Overall survival, event-free survival (EFS), relapse incidence (RI) and transplant-related mortality (TRM) of 100 children with juvenile myelomonocytic leukemia (JMML) transplanted after a conditioning regimen including busulfan, cyclophosphamide and melphalan from a matched related (n = 48) or a matched unrelated (n = 52) donor.¹³